Literature DB >> 2782920

[Pharmacokinetics of cisplatin and vindesine in a patient with chronic renal failure undergoing hemodialysis].

H Ayabe1, T Uchikawa, K Kimino, Y Tagawa, K Kawahara, M Tomita.   

Abstract

Plasma total platinum and vindesine levels were monitored in a patient with chronic renal failure undergoing hemodialysis. Plasma levels of cisplatin were determined as platinum by atomic absorption spectrophotometry, and plasma vindesine levels were measured by radioimmunoassay. Fifty mg. of cisplatin in combination with 3 mg. of vindesine were infused for 60 minutes before dialysis. During dialysis, plasma total platinum levels decreased rapidly in a biphasic fashion and 1.76 at 30 hours after infusion. Plasma vindesine levels declined with higher concentration. In conclusion, it is considered that cisplatin and vindesine can be given to anuric patients undergoing hemodialysis. However, it is suggested that smaller doses should be given to prevent side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782920

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  4 in total

Review 1.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

3.  Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer.

Authors:  Kotaro Sato; Yasushi Hayashi; Kazuyo Watanabe; Ryoko Yoshimi; Hideharu Hibi
Journal:  Nagoya J Med Sci       Date:  2019-08       Impact factor: 1.131

4.  Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer.

Authors:  R Watanabe; Y Takiguchi; T Moriya; S Oda; K Kurosu; N Tanabe; K Tatsumi; K Nagao; T Kuriyama
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.